Welcome to UroSens – developing novel urine diagnostic tests for prostate and bladder cancer

UroSens Ltd, with research facilities on the Babraham Research Campus, Cambridge and Commercial premises in Sunderland, is developing proprietary diagnostic immunoassays for the detection of prostate and bladder cancer using urine samples.
The Company has a worldwide exclusive license, from Cancer Research Technology Ltd, for the exploitation of MCM cancer biomarkers in the diagnosis of bladder and prostate cancer, using quantitative immunoassays. MCM proteins are excellent biomarkers, being directly involved in cell replication and are shed into urine by both prostate and bladder tumours. Picture of LFD in somebodies hand The ubiquitous nature of MCMs, and their direct involvement in cell replication, means that the Company can develop a single test format that works for both conditions.

The non-invasive, urine-based ELISA and Point-of Care tests meet the increased demand for cost-effective healthcare technologies that not only enhance patient care but help to reduce overall healthcare costs by improving patient outcomes.

UroSens will commercialise ELISA and point-of-care urine tests for prostate and bladder cancer for use in the urology clinic, hospital lab and the GP’s surgery.